Status:
COMPLETED
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for diabetic macular edema.
Eligibility Criteria
Inclusion
- Provided signed, written informed consent
- 20 years of age or older with diabetic macular edema
Exclusion
- Active proliferative diabetic retinopathies (PDR) in the study eye
- Uncontrolled diabetes mellitus and hypertension
- Known steroid-responder
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01411254
Last Update
July 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santen study sites
Osaka, Osaka, Japan